CD274 and cancer: It is noteworthy that the majority of cancer patients are treated with genotoxic, DNA-damaging chemicals prior to PLB; thus, our hypothesis advancing the understanding of the PD-L1, may unravel other molecular/immunologic changes applicable to the treatment of PLB-non-responders using combination therapy.